Kong, Tim https://orcid.org/0000-0002-3240-8989
Mabry, Alex https://orcid.org/0000-0003-1635-8800
Highkin, Maureen
Wang, Anthony Z.
Hoog, Jeremy
Guo, Zhanfang
Gonzales-Gonzales, Adrian
Thomas, Shana
Song, Yingduo https://orcid.org/0009-0002-9496-6270
Gao, Feng
Opyrchal, Mateusz https://orcid.org/0000-0003-2454-7441
Peterson, Lindsay
Ademuyiwa, Foluso https://orcid.org/0000-0002-6766-2258
Margenthaler, Julie
Aft, Rebecca
Glover-Collins, Katherine
Nehring, Leslie
Tao, Yu
Sanati, Souzan
Hagemann, Ian S. https://orcid.org/0000-0002-3855-9745
Boulos, Fouad
Holt, Matthew
Ding, Li https://orcid.org/0000-0003-1517-2975
Zhu, Wenge https://orcid.org/0000-0001-9113-5020
Oh, Stephen T. https://orcid.org/0000-0002-8564-5400
Wang, Jianxin https://orcid.org/0000-0002-0998-4996
Witkiewicz, Agnieszka K.
Knudsen, Erik S. https://orcid.org/0000-0002-5130-5969
Bose, Ron https://orcid.org/0000-0003-1977-8894
Weber, Jason D. https://orcid.org/0000-0002-1069-6983
Goetz, Matthew
Northfelt, Donald
Luo, Jingqin https://orcid.org/0000-0003-2759-3072
Ma, Cynthia X. https://orcid.org/0000-0002-8156-7492
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | NCI | Division of Cancer Epidemiology and Genetics, National Cancer Institute (P30 CA91842)
Breast Cancer Research Foundation
Article History
Received: 17 October 2024
Accepted: 7 January 2026
First Online: 27 January 2026
Competing interests
: C.X.M. received research funding from Pfizer Pharmaceuticals. C.X.M. received advisory/consulting fees from Eli Lilly, Stemline, Novartis, TerSera Therapeutics, AstraZeneca, Olaris, Pfizer, Stemline, Daiichi, Merck, Regor Therapeutics, Danatlas. I.S.H. received advisory board fees from AstraZeneca. The remaining authors declare no competing interests.